Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Gryphon Bio, Inc. has announced its pursuit of observational clinical studies with partners at multiple U.S. and ...

Delray Medical Center cut the ribbon on its newest high-tech machine that targets brain areas to treat movement disorders ...

A new study from Karolinska Institutet and Mayo Clinic has revealed important insights into brain degeneration in dementia ...

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzhei ...

ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline.People with ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...

Knowing the warning signs of dementia is important for dealing with the debilitating condition that currently has no cure.